INTERVIEW: Norwest Venture Bullish On Digital Health Outlook
This article was originally published in Clinica
Executive Summary
Venture funding for medtech start-ups continues to lag far behind their pharma counterparts, but companies developing digital health devices are increasingly popular with investors. Robert Neil speaks to Casper de Clercq of Norwest Venture Partners about the VC’s latest $1.2bn, where the funds will go, the health of the overall medtech funding market and his take on where digital health is going
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.